Genetic Alterations and Transcriptional Expression of m6A RNA Methylation Regulators Drive a Malignant Phenotype and Have Clinical Prognostic Impact in Hepatocellular Carcinoma

Gui-Qi Zhu,Lei Yu,Yu-Jie Zhou,Jun-Xian Du,Shuang-Shuang Dong,Yi-Ming Wu,Ying-Hong Shi,Jian Zhou,Jia Fan,Zhi Dai

DOI: https://doi.org/10.3389/fonc.2020.00900

IF: 4.7

2020-07-21

Frontiers in Oncology

Abstract:<span><strong>Background:</strong> N6-methyladenosine (m⁶A) RNA methylation, associated with cancer initiation and progression, is dynamically regulated by the m⁶A RNA regulators. However, its role in liver carcinogenesis is poorly understood.<strong>Methods:</strong> Three hundred seventy-one hepatocellular carcinoma (HCC) patients from The Cancer Genome Atlas database with sequencing and copy number variations/mutations data were included. Survival analysis was performed using Cox regression model. We performed gene set enrichment analysis to explore the functions associated with different HCC groups. Finally, we used a machine-learning model on selected regulators for developing a risk signature (m⁶Ascore) The prognostic value of m⁶Ascore was finally validated in another two GEO datasets.<strong>Results:</strong> We demonstrated that 11 m⁶A RNA regulators are significantly differentially expressed among 371 HCC patients stratified by clinicopathological features (P&lt;0.001). We then identified two distinct HCC clusters by applying consensus clustering to m⁶A RNA regulators. Compared with the cluster2 subgroup, the cluster1 subgroup correlates with poorer prognosis (<i>P</i> &lt; 0.001). Moreover, the cell cycle, splicesome and notch signaling pathway are significantly enriched in the cluster1 subgroup. We further derived m⁶Ascore, using four m⁶A regulators, predicting HCC prognosis well at three (AUC = 0.7) or 5 years (AUC=0.7) in validation. The prognostic value of m⁶Ascore also was validated successfully in two GEO datasets (<i>P</i> &lt; 0.05). Finally, we discovered that mutations and copy number variations of m⁶A regulators, conferring worse survival, are strongly associated with TP53 mutations in HCC.<strong>Conclusions:</strong> We find a significant relationship between the alterations and different expressions causing increased m⁶A level and worse survival, especially in TP53-mutated HCC patients. Genetic alterations of m⁶A genes might cooperate with TP53 and its regulator targets in the HCC pathogenesis. Our m⁶Ascore may be applied in the clinical trials for patient stratification in HCC.</span>

oncology